US drugmaker Amneal (NYSE: AMRX) has announced that the US Food and Drug Administration (FDA) has approved the company’s Biologics License Application (BLA) for pegfilgrastim-pbbk, a biosimilar referencing Neulasta.
The Amneal’s biosimilar version of Amgen’s (Nasdaq: AMGN) Neulasta will be marketed under the proprietary name Fylentra.
Fylentra was developed in collaboration with Chicago-based Kashiv Biosciences. It is used to treat neutropenia (low neutrophils which are a type of white blood cells that fight infection) which is commonly experienced by patients undergoing chemotherapy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze